A 30-year-old man, whohad a repeated history of relapsed Hodgkin's lymphoma over 7 years, developed bilateral pleural effusion and chest wall involvement. He was treated with weekly irinotecan hydrochloride (CPT-ll ; 80 mg/m2/week). Partial response was observed after two cycles of irinotecan. Neutropenia and diarrhea were tolerable. This case demonstrated that irinotecan has a therapeutic effect in patients with relapsed Hodgkin's lymphoma. (Internal Medicine 41 : 648-650, 2002) 
Introduction
Irinotecan hydrochloride (CPT-1 1 ), a DNAtopoisomerase-1 inhibitor, has been shownto have strong antitumor activity against several tumors (1) (2) (3) . Several clinical studies have shown that irinotecan has beneficial effects in patients with malignant lymphoma, especially relapsed and/or refractory nonHodgkin's lymphoma (4) (5) (6) . However, the dose and schedule are still controversial. In addition, little information has been reported on the efficacy of irinotecan in patients with Hodgkin's lymphoma. Wepresent here a case of relapsed Hodgkin's lymphomawho showed a good outcome with irinotecan.
Case Report
In November 1994, a 24-year-old man was admitted to our hospital because of chest pain. His chest radiograph showed an anterior mediastinal mass surrounding the vessels. Laboratory findings including human chorionic gonadotropin and ocfetoprotein were normal. Percutaneous biopsy was performed. Althoughthe specimens were too small to makea definite diagnosis, germcell tumor or Hodgkin's lymphomawassuspected. He was treated with 3 cycles of cisplatin and etoposide (PVP) chemotherapy. Good partial response was achieved and thoracic radiotherapy (46 Gy) followed. The first relapse occurred in October 1998. He developed left cervical lymph node swelling and lower abdominal huge mass. The histological diagnosis of Hodgkin's lymphoma (mixed cellularity type) was made by cervical lymph node biopsy. He was treated with 6 cycles ofABVD(adriamycin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2, day 1 and 15, respectively) chemotherapy and radiotherapy for the abdominal mass (40 Gy). Complete remission was achieved after the therapy. However, right cervical lymphnode swelling was again found in August 2000. Radiotherapy for a right neck lesion (46 Gy) was performed. However, body weight loss and emaciation developed. He developed right chest pain, cough and dyspnea in October, 2000. A radiograph showed a pleural effusion in right lung side. Thoracocentesis was performed twice and right pleural effusion was drained. The cytology was class II. However, subsequent radiograph revealed a pleural effusion in both sides and a right chest wall mass (Fig. 1) . Chest computed tomography also showed similar findings (Fig. 2) . Laboratory findings were: white blood cell (WBC) count 7,020/|al, hemoglobin (Hb) 10.8 g/dl, lactate dehydrogenase (LDH) 299 U/ml. Soluble interleukin 2 receptor (SIL-2R) was 7,980 U/ ml. He was treated with irinotecan (80 mg/m2, day 1, 8, 15). The informed consent was obtained verbally. His chest radiograph was almost normal after 2 cycles of irinotecan therapy (Fig. 3) . The value of SIL-2R also returned to almost normal (829 U/ml) in January 2001. Irinotecan (80 mg/m2) therapy was repeated biweekly without recurrence for 1 0 months. There were no significant toxicity. However, pleural effusion in both sites was again increased in October 2001.
Discussion
Several clinical and experimental studies have suggested a lack of cross -resistance between irinitecan and other anticancer agents (1-3) . Irinotecan has shown a good response in patients with relapsed and/or refractory malignant lymphoma (4) (5) (6) . With regard to therapeutic efficacy of irinotecan in patients CPT-1 1 and Hodgkin's Lymphoma with Hodgkin's lymphoma, there is little information. One of response. The response rates seem to be low compared with three patients with Hodgkin's lymphoma in early phase II (4) those of non-Hodgkin's lymphoma (42%; 26/62 cases) (4). and 0 of 4 patients in late phase II study (5) achieved partial However, the present case suggested that CPT-ll is efficacious We used 80 mg/m2 of irinotecan weekly every 3 weeks, because weekly administration is suitable for the treatment of outpatients. This regimen has been the frequency used in patients with solid tumors. Although the present case had a good response with this treatment regimen, the dose and the schedule of irinotecan should be discussed. Antitumor activity of SN-38, the active metabolite of irinotecan, has been thought to be 100 to 1,000 times stronger than that of irinotecan (1) . Based on clinical studies by Nakano et al, intravenous administration of irinotecan produced adequate distribution of irinotecan and SN-38 in pleural fluid, and SN-38 showed a higher concentration than irinotecan in the pleural space (7) . In addition, we have previously shown that SN-38 has better transfer into lung lymph circulation following intravenous administration of irinotecan in an animal model (8) . The extent of the disease in the present case was mainly in the intrathoracic region. Wespeculate that the beneficial outcome by irinotecan in the present case is related to these pharmacokinetic characteristics of irinotecan. In summary, the present case demonstrated that irinotecan has a therapeutic effect in patients with refractory and relapsed Hodgkin's lymphoma. Although the dose and schedule of irinotecan are still undetermined, our case mayprovide optional information into the chemotherapeutic strategy for refractory malignant lymphoma.
